These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 24246236

  • 1. [Thrombocytopenia due to omalizumab].
    Lopez-Rodriguez JA, Santos Franco L.
    An Pediatr (Barc); 2014 Jun; 80(6):413-4. PubMed ID: 24246236
    [No Abstract] [Full Text] [Related]

  • 2. Churg-Strauss syndrome in a patient treated with omalizumab.
    Cisneros C, Segrelles G, Herráez L, Gonzalez A, Girón R.
    J Investig Allergol Clin Immunol; 2013 Jun; 23(7):515-6. PubMed ID: 24654320
    [No Abstract] [Full Text] [Related]

  • 3. Omalizumab 75 mg. Whatever the dosage, the drug should be avoided in severe persistent asthma.
    Prescrire Int; 2011 Nov; 20(121):262. PubMed ID: 22066310
    [No Abstract] [Full Text] [Related]

  • 4. Drugs to avoid during pregnancy: omalizumab and montelukast, too many uncertainties.
    Prescrire Int; 2014 Feb; 23(146):51. PubMed ID: 24669391
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Omalizumab under 12 years old: real-life practice.
    Pite H, Gaspar Â, Paiva M, Leiria-Pinto P.
    Allergol Immunopathol (Madr); 2013 Feb; 41(2):133-6. PubMed ID: 22560014
    [No Abstract] [Full Text] [Related]

  • 8. Omalizumab: NICE to USE you, to LOSE you NICE.
    Bush A, Pavord ID.
    Thorax; 2013 Jan; 68(1):7-8. PubMed ID: 23229814
    [No Abstract] [Full Text] [Related]

  • 9. Omalizumab and the risk of malignancy: results from a pooled analysis.
    Busse W, Buhl R, Fernandez Vidaurre C, Blogg M, Zhu J, Eisner MD, Canvin J.
    J Allergy Clin Immunol; 2012 Apr; 129(4):983-9.e6. PubMed ID: 22365654
    [Abstract] [Full Text] [Related]

  • 10. Omalizumab in the treatment of asthma.
    Tan R, Corren J.
    Expert Rev Respir Med; 2011 Dec; 5(6):747-56. PubMed ID: 22082161
    [Abstract] [Full Text] [Related]

  • 11. Summaries for patients. Omalizumab therapy for patients with severe asthma.
    Ann Intern Med; 2011 May 03; 154(9):I28. PubMed ID: 21536934
    [No Abstract] [Full Text] [Related]

  • 12. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy.
    Namazy J, Cabana MD, Scheuerle AE, Thorp JM, Chen H, Carrigan G, Wang Y, Veith J, Andrews EB.
    J Allergy Clin Immunol; 2015 Feb 03; 135(2):407-12. PubMed ID: 25441639
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study.
    Maselli DJ, Singh H, Diaz J, Peters JI.
    Ann Allergy Asthma Immunol; 2013 Jun 03; 110(6):457-61. PubMed ID: 23706716
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Omalizumab in asthma: an update on recent developments.
    Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J, Erpenbeck VJ, Holgate S.
    J Allergy Clin Immunol Pract; 2014 Jun 03; 2(5):525-36.e1. PubMed ID: 25213045
    [Abstract] [Full Text] [Related]

  • 16. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
    Tzortzaki EG, Georgiou A, Kampas D, Lemessios M, Markatos M, Adamidi T, Samara K, Skoula G, Damianaki A, Schiza S, Tzanakis N, Siafakas NM.
    Pulm Pharmacol Ther; 2012 Feb 03; 25(1):77-82. PubMed ID: 22155001
    [Abstract] [Full Text] [Related]

  • 17. [Omalizumab therapy in adolescents with severe allergic asthma - results of a post-marketing surveillance].
    Klyucheva M, von Berg A, Gappa M, Suerbaum C, Berdel D.
    Pneumologie; 2013 Apr 03; 67(4):233-7. PubMed ID: 23576201
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Eligibility for treatment with omalizumab in Italy and Germany.
    Buhl R, Marco AG, Cohen D, Canonica GW.
    Respir Med; 2014 Jan 03; 108(1):50-6. PubMed ID: 24315468
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.
    Somerville L, Bardelas J, Viegas A, D'Andrea P, Blogg M, Peachey G.
    Curr Med Res Opin; 2014 Jan 03; 30(1):59-66. PubMed ID: 24028677
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.